{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:44:41Z","timestamp":1791531881724,"version":"4.3.4"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100012399","name":"HHS | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201400002C"],"award-info":[{"award-number":["HHSO100201400002C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,1,27]]},"abstract":"<jats:p>The most common mechanism of resistance to \u03b2-lactams antibiotics in Gram-negative bacteria is production of \u03b2-lactamase enzymes capable of cleaving the \u03b2-lactam ring. Inhibition of \u03b2-lactamase activity with small-molecule drugs is a proven strategy to restore the potency of many \u03b2-lactam antibiotics.<\/jats:p>","DOI":"10.1128\/aac.01935-19","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T06:15:32Z","timestamp":1573020932000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":69,"title":["Biochemical Activity of Vaborbactam"],"prefix":"10.1128","volume":"64","author":[{"given":"Ruslan","family":"Tsivkovski","sequence":"first","affiliation":[{"name":"Qpex Biopharma, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lomovskaya","sequence":"additional","affiliation":[{"name":"Qpex Biopharma, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01076-18"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2019.04.011"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0159-8"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp197"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.01.018"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.12.101"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw593"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv166"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz330"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz026"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00678-15"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02097-16"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2510453"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja0288338"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm980343w"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02643-15"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02641-15"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00127"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00711-16"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01904-17"},{"key":"e_1_3_3_22_2","unstructured":"Melinta Therapeutics. 2017. VABOMERE (meropenem and vaborbactam) for injection for intravenous use prescribing information. Melinta Therapeutics Inc New Haven CT. http:\/\/www.vabomere.com\/media\/pdf\/vabomere-us-prescribing-information.pdf."},{"key":"e_1_3_3_23_2","unstructured":"European Medicines Agency. 2018. Vaborem (meropenem-vaborbactam) prescribing information. European Medicines Agency Amsterdam The Netherlands. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaborem-epar-product-information_en.pdf."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01694-17"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2050631"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01636-15"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00158-15"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.02.065"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3100"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02260-16"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12406"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.37.4.851"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2090229"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.485979"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205073109"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1222343"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2082"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90609-5"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01935-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01935-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:07:31Z","timestamp":1645466851000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01935-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,27]]}},"alternative-id":["10.1128\/AAC.01935-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.01935-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"2019-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01935-19"}}